Apremilast was the second oral PDE4 inhibitor introduced to the market, receiving initial approval in 2014 for the treatment of psoriasis, followed by approvals for psoriatic arthritis in 2014, pediatric psoriasis in 2015 and Behçet’s disease in 2019. The gene discussed is PDE4A; the disease is psoriasis.